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Abstract 
Background: Insulin sensitivity is impaired by PGE2, a major product of 
cyclooxygenase-2 (COX-2), which thus interferes with cellular glucose uptake following 
a glucose load. As shown in erythrocytes, PGE2 formation is inhibited by annexin A7. 
The present study defined the role of annexin A7 in glucose metabolism. 
 
Methods:  Gene-targeted mice lacking annexin A7 (annexinA7-/-) were compared to 
wild type mice (annexinA7+/+). 6-Keto-prostaglandin-F1α (6-Keto-PGF1α) was 
determined by ELISA to estimate COX-2 activity in serum. Hepatic COX activity was 
determined by an ELISA assay. Glucose and insulin serum concentrations were 
determined following an intraperitoneal glucose load and glucose serum levels after 
intraperitoneal injection of insulin. Experiments were done without and with 
pretreatment of the mice with COX inhibitor aspirin. 
 
Results: The serum 6-Keto-PGF1α level and hepatic COX activity were significantly 
higher in annexinA7-/- than in annexinA7+/+ mice. The intraperitoneal glucose tolerance 
test revealed decreased glucose tolerance in annexinA7-/- mice compared to annexinA7+/+ 
mice. Intraperitoneal insulin injection decreased the serum glucose level in both 
genotypes, an effect significantly less pronounced in annexinA7-/- than in annexinA7+/+ 
mice. Intraperitoneal glucose administration resulted in higher serum insulin 
concentrations in annexinA7-/- than in annexinA7+/+ mice. Aspirin pretreatment lowered 
the increase in insulin concentration following glucose injection in both genotypes and 
virtually abrogated the differences in serum insulin between the genotypes. Moreover, 
aspirin pretreatment improved glucose tolerance in annexinA7-/- mice. 
 
Conclusions: Annexin A7 influences insulin sensitivity of cellular glucose uptake and 
thus glucose tolerance. These effects depend on COX activity.  
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1.Introduction 
 
Diabetes mellitus is one of the major diseases in modern time, which affects around 6 
million people in Germany according to the survey of the Robert Koch Institute in 2009 
(http://www.rki.de). International Diabetes Federation (IDF) estimates that the number 
of people suffered from diabetes will rise to 552 million by 2030 globally 
(http://www.idf.org). Diabetes mellitus has been seen as a serious health threat in the 
worldwide, therefore early interference is urgently required. Type 2 diabetes mellitus is 
characterized by insulin resistance or relative insulin deficiency, which is a more 
prevalent form and comprises of 90% of people with diabetes around the world1 . It is 
strongly associated with obesity, hypertension and dyslipidemia2 . However, the precise 
mechanisms triggering the insulin resistance remain unclear. 
 
 
1.1 Annexin and annexin A7 
 
Annexins are a family of calcium dependent phospholipids binding proteins, which are 
found in almost all tissues and cell types. There are more than 160 unique annexin 
proteins from fungi and protists to plants and vertebrates. But only twelve annexin 
subfamilies have been discovered in humans (annexin A1-annexin A11 and annexin 13)3. 
These proteins are mainly distributed in the inner surface of the plasma membrane 
related to cytoskeleton and cellular structures. 
 
In structure, there are four segments or annexin repeats, which form highly α-helical and 
tightly entwined bands, in an annexin core (Figure 1). The segments form two main 
convex-concave sides. Each annexin shares a common C-terminal protein core that 
contains the calcium binding sites (yellow ball in Figure 1). The more concave side is 
variable N-terminal region. It has ligand binding sites that can bind some proteins or 
signal molecules in cytoplasm and play its function. Therefore, the latter is seen as the 
deciding factor of individual annexin function 4. Several members of annexin have been 
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shown to bind the S100 calcium-binding proteins, actin and formyl peptide receptor 
(FPR), which can regulate a variety of cellular activities such as differentiation and 
apoptosis5,6. 
 
 
 
 
Figure 1. The three-dimensional crystal structure of human annexin A5. The four annexin 
repeats that are given in green (repeat I), blue (repeat II), red (repeat III), and violet/cyan (repeat 
IV). The yellow ball indicates Ca2+. Modified from Gerke V and Moss SE (2002) 7. 
 
The conservation of multiple annexins in many cell types suggests its fundamental role 
in cell biology. The development of knockout mice has provided great insight into the 
functions of annexins A1, A2, A5, A6，A7 and A8. Annexin A1 can cause changes in the 
inflammatory response and effects glucocorticoids regulation8. Annexin A1 deficient 
mice increase adipose tissue, suggesting annexin A1 as an important modulator in 
adiposity9. Annexin A2 is expressed at the surface of vascular vessels and related to 
blood clotting10. Annexin A2 deficient mice have defects in fibrin homeostasis, effecting 
the neovascularization11. Annexin A5 which is an anticoagulation may be linked to the 
development of obesity12. Annexin A6 expression, which is associated with tumor, 
suppress the cancer proliferation by inhibition of Ras /MAPK signaling pathway13,14. 
Annexin A6 also can regulate the mitochondrial morphogenesis, affecting the cellular 
energy supply by inhibiting Drp1 activity15. Annexin A8 affects the recruitment of 
leukocyte via stimulating the surface delivery CD63 in endothelial cells 16.  
 
Annexin A7 (synexin) was the first annexin protein to be isolated and described17. It was 
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isolated as a reagent that mediated aggregation of chromaffin granules and fusion of 
phospholipids membranes in the presence of Ca2+. Annexin A7 differs from other 
annexin proteins in that it possesses extraordinary long amino terminus17. This amino 
terminus carries an exon of 22 amino acids generated by alternative splicing leading to 
two isoforms: 47 and 51 kDa. Both of them widely expressed in murine and human 
tissues, but in the skeletal muscle, myocardium only 51 kDa isoforms is expressed 18, in 
platelets only 47 kDa expressed19. 
 
Annexin A7 influences many functions and metabolic processes. In cardiovascular 
research, annexin A7 deficiency may disturb calcium normal operation and conduction, 
which leads to severe electrical instability in the murine heart 20. Lack of annexin A7 
enhances eryptosis of erythrocytes, due to calcium overload, shorten its life of red blood 
cells and lead to anemia 21. In tumors, high annexin A7 expression is associated with 
high aggressive potential in hormone-relative tumors such as malignancies of liver 
cancer, gastric cancer, nasopharyngeal carcinoma, colorectal cancer and breast cancer22. 
However, annexin A7 also has a tumor-suppression role in glioblastoma, glioblastoma 
multiforme, melanoma and prostate cancer. Annexin A7 is seen as a potential target in 
clinical diagnosis and treatment of certain tumors22. Further, annexin A7 takes part in the 
regulation of gastric acid secretion. Gastric acid cannot be upregulated by the 
glucocorticoid dexamethasone without annexin A723. The isoform of annexin A7 
inhibits PGE2 formation and contributes to the regulation of secretion. According to a 
malaria study in annexin A7 knockout mice, parasites enhance PGE2 formation and 
calcium permeability, while the wide type group significantly decreases it24. Annexin A7 
is also abundantly expressed in some inflammatory diseases, such as inflammatory 
myopathies25.  
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1.2 COX and prostaglandin  
 
Cyclooxygenase (COX) is a central and rate-limiting enzyme responsible for the 
production of prostaglandins. There are main three known isoforms of COX: COX-1, 
COX-2 and COX-3. COX-1 is expressed in various of tissues, particularly in gastric, 
bowel mucosa and kidney 26.COX-1 is related to the production of prostaglandins (PGs) 
which are important lipid compounds for regulating normal physiological function, such 
as stomach mucous production, regulation of gastric acid and normal platelets mediation 
27. The expression of COX-2, as a part of immune response, is much lower than COX-1 
in normal physiology. COX-2 can be stimulated by inflammatory cytokines, growth 
factors, carcinogens etc.. Aberrant COX-2 activation and PGs production are associated 
with infection and cancers (Figure 2) 28. COX-3 is a new isoform and seen as a COX-1 
variant. Similar with COX-1 function, COX-3 cannot be induced by acute inflammatory 
stimulation29.  
 
 
 
Figure 2. COX-1 and COX-2 pathways. COX-1 is constitutive and regulates normal 
physiological function. COX-2 is inducible by cytokines etc. and related to inflammation and 
cancers.   
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Prostanoids are a group of fatty acid derivatives including PGs, prostacyclin and 
thromboxane (TXA). COX enzyme converts arachidonic acid (AA) to prostaglandin H2 
(PGH2), through peroxidase activity. PGH2 is a precursor of the series-2 prostanoids and 
acted upon by one of a group of synthases that can modify the cyclopentane and produce 
different kinds of prostaglandins. Non-steroidal anti-inflammatory drugs (NSAIDs), 
such as aspirin, can reduce the PGs formation by inhibiting COX enzyme, which directly 
impacts the quantity of PGs production (Figure 3). 
 
 
 
 
Figure 3. Prostaglandin biosynthetic pathways.  Arachidonic acid is catalyzed by COX-1 or 
COX-2 resulting in synthesis of PGH2. PGH2 is converted to one of prostaglandins, dependent 
upon the end synthase. NSAIDS reduce the PGs through COX enzyme inhibiting. 
 
 
1.3 PGE2 and its effect in glucose metabolism 
 
PGE2 is an important mediator of immune-inflammatory responses inducing 
vasodilation by smooth muscle relaxation, stimulating fever by acting on the 
hypothalamus, and causing pain by sensitizing peripheral nociceptors30. PGE2 is 
synthesized by the action of prostaglandin E2 synthase (PGES) which acts on COX 
derived PGH2 and released by macrophages 31.  
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PGE2 can conduct the signal through four different G-protein coupled receptors, termed 
E series prostaglandin receptors (EP1R-EP4R) 32. Each receptor is encoded on a separate 
gene and differs in structure and function. EP3R holds prominent position and plays 
regulatory role in β-islet cells 33. 	  
Recent evidence suggests PGE2 has a significant role in obesity and diabetes mellitus. 
PGE2 can increase leptin release from adipose tissue and inhibit lipolysis in white 
adipose tissue, predicting that PGE2 signaling is important in the regulation of body 
weight and metabolic homeostasis34. Mice lacking EP3R can develop obesity and have a 
significantly higher body weight than wild type group when aged 10 weeks 35. High 
level of PGE2 and up-regulation of COX-2 in human adipocytes have been observed in 
vitro 36. Mice lacking phospholipase A2, an essential component in PGE2 biosynthesis, 
have a reduced PGE2 concentration in adipose tissue and lowered weight gain 37. 
Moreover, PGE2 may simulate oncostatin M (OSM) which is produced by Kupffer cells, 
thereby resulting in insulin resistance in hepatocytes 38. EP1R in the kidney play a 
critical role in the development of diabetic nephropathy39. The synthesis of PGE2 and  
EP3R in β-cells can be up regulated in type 2 diabetes mellitus and result in β-cell 
dysfunction40. The higher levels of PGE2 is also observed in patients with diabetic 
retinopathy suggesting that PGE2 may have a pathogenic role in diabetic retinopathy41. 
 
Hypertension is a part of insulin resistance syndrome 42. PGE2 can affect and regulate the 
peripheral vascular tone by EPR. EP1R and EP3R, which are mainly expressed in 
pulmonary vascular vessels and nervous system, are functionally associated with 
vasoconstriction. Knocking out EP1R or EP3R causes the hypotension in mice 43,44. In 
the kidney, COX-2 is an important mediator of the renin-angiotensin system. PGE2 and 
PGI2 from renal medullary play a critical role in regulating the secretion of renal rennin 
and the reabsorption of sodium and water in the medullary thick ascending limb and 
collecting duct. Mice with COX-2 deficiency or blocking COX-2 can decrease renal 
rennin production and secretion and induce mild to moderate elevation of blood pressure 
45.  
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1.4 Insulin action and signaling 
 
Insulin is an important peptide hormone in the metabolism of glucose and fat. It can 
stimulate cells in liver, skeletal muscle and adipose to absorb and utilize glucose from 
the blood and keep glycemic level homeostasis within the body. In the liver, insulin 
promotes glycogen synthesis through stimulating glycogen synthase (GS) and inhibiting 
glycogen phosphorylase. In muscle and adipose tissue, insulin induces an uptake of 
glucose by increasing glucose transporter type 4 (GLUT4) expression on the cell surface 
and then forms glycogen in muscle or converts the glucose to fatty acids in fat46. Hence, 
loss of insulin secretion or resistance to its actions can lead to high blood glucose 
concentration and result in diabetes mellitus. 
 
There are two major signal pathways that conduct to effectors after insulin receptor 
substrate (IRS) binding with insulin. One pathway is metabolism signaling through IRS 
and phosphatidylinositol-3-kinase (PI3K) pathway, which regulates carbohydrate, fat, 
and protein metabolism or increases endothelial NO synthase (eNOS). The other is 
mitogenic pathway through Shc/RAS/MAPK that regulates gene transcription and cell 
proliferation. Any deficiency or mutation of the genes in this pathway or effected by 
other factors may lead to the disorder of the metabolic action of insulin.  
 
Insulin receptors are widely expressed at the cell surface in insulin responsive tissues. It 
consists four parts (Figure 4), two extracellular insulin-binding sites (α- peptides chains, 
yellow color) and two transmembrane sites (β- peptides chains, pink color). The β- 
peptides chains are stimulated by autophoshorylation when α- peptides chains bind to 
insulin. It provides specific sites for binding the IRS protein and some downstream 
signaling molecules e.g. Shc protein47. IRS is activated through a phosphotyprosine 
process when binding to the insulin receptor. 
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Figure 4. Insulin receptor structure. Insulin receptor monomer composed of α (yellow) and β 
subunit (purple). They are connected by disulfide bounds to form a functional receptor48. 
 
There are two main types of insulin receptor substrates: IRS-1 and IRS-2. Both of them 
are expressed in most insulin sensing-tissues. IRS-1 is related to GLUT4, which is an 
important glucose transporter in liver and adipose tissue. The main effect of IRS-1 is to 
promote skeletal muscle or adipose cells to utilize glucose whereas the IRS-2 regulates 
the function of β-islet cell and promote glycogen synthase (GS) in hepatocytes. 
Phosphorylated IRS activates PI3K and then results in serine/threonine-specific protein 
kinase (AKT) and 3-phosphoinositide-dependent protein kinase-1 (PDK-1) 
phosphorylation. AKT is a central intermediate for many metabolism processes in cells. 
There are three isoforms of AKT: AKT1, AKT2 and AKT3. AKT1 and AKT2 play the 
dominant action in insulin response in skeletal muscle and adipose tissue, whereas 
AKT3 can be activated in the liver49,50. AKT phosphorylates AS160, a protein that is 
required for GLUT4 translocation in cell51. AKT was also shown to be one of the insulin 
mediated kinases that phosphorylates glycogen synthase kinase-3 (GSK-3)52. This 
intracellular pathway promotes glycogen synthesis in liver and muscle via glycogen 
synthase activation and glucose uptake in adipose tissue by translocation GLUT4 to the 
cell surface membrane (Figure 5)53.  
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Shc/Ras/MAPK signaling pathway is another way to regulate the insulin effects on cells. 
It can transfer the signal from a receptor at the surface to the inside or nucleus of the cell. 
It mainly includes three ways ERK1/2, JNK and p38. ERK1/2 signal pathway is known 
as the most classic in MAPK pathways, which can be activated by phosphorylated Ras 
or some small molecules such as insulin like growth factor (IGF) and prostaglandins. 
ERK1/2 can cross through the membrane of cells or nucleus and plays an important role 
in cell proliferation and gene expression54. 
 
 
Figure 5. Insulin signaling through its metabolic and mitogenic pathways. Insulin induces 
glucose uptake in liver, muscle and adipose tissue through PI3K-AKT pathway and regulates 
gene function through Shc/Ras/MAPK pathway. Modified from Chiu and Cline (2010)48.   
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1.5 Insulin signaling defects in insulin resistance 
 
Insulin resistance is the common pathophysiologic basis of type 2 diabetes mellitus and 
the exact mechanism remains unclear. However, it has been demonstrated that insulin 
resistance is influenced by both environmental and genetic factors55.  
 
The first step of insulin action is initiated by the binding and activation of its receptors, 
which are expressed on the cell surface. It has been observed that IRS-1 low expression 
in skeletal muscle and adipocytes from patients with type 2 diabetes mellitus 56,57. 
Several studies showed the insulin receptor unaltered or impaired in the type 2 diabetes 
mellitus 58. The mutation in exon 20 of the insulin receptor gene may be an important 
reason for genetic insulin resistance 59. As described above, IRS family has critical 
physiologic functions on insulin. IRS-1 knockout mice can develop a mild insulin 
resistance 60. However, disruption of IRS-2 genes causes a severe insulin resistance and 
develops to type 2 diabetes mellitus eventually61. Researchers found impaired PI3K 
activity in the liver or skeletal muscle from Type2 diabetes both in vivo and vitro62-64. 
AKT is also an essential protein in the normal glucose metabolism. AKT2 deficient mice 
develop insulin resistance and diabetes-like syndrome65. Over expression of GLUT4 in 
adipose tissue enhances insulin sensitivity and glucose tolerance. Adipose tissue loss of 
GLUT4 results in a degree of insulin resistance66. 
 
Furthermore, some studies reveal that insulin signaling can be affected by other elements 
such as the inflammatory and hormonal factors, endoplasmic reticulum (ER) stress and 
metabolic ‘overload’ in insulin-sensing tissues67. TNF-α and IL-6 are multi functional 
cytokines. Increased TNF-α expression has been discovered in adipose tissues of obesity 
people68. Inhibiting phosphorylation of IRS-1 and disrupting the translocation of GLUT4 
is the main effect of TNF-α in insulin resistance 69,70. IL-6 can inhibit insulin receptor 
transduction via inducing the suppressors’ cytokine signaling-3 (SOCS-3) in hepatocytes. 
SOCS-3 is a direct inhibitor of insulin receptor autophoshorylation in the cell 71,72. 
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Obesity or over-lipid accumulation is associated with mechanical stress in the cell. ER is 
a critical player in cell stress and ER stress can significantly decrease insulin-stimulated 
tyrosine phosphorylation of IRS-1 in hepatocytes and hypoactive JNK pathway 73. 
Ingesting high-fat for a long period or infusing the lipid directly in rodents can lead to 
the accumulation of lipids, including triglycerides (TAGs), diglycerides (DAGs), and 
ceramides, and inducing insulin resistance74,75. Lipids over accumulation within liver 
cells and insulin resistance are strongly coupled76, which triggers activation of novel 
protein kinases C (PKC) , relate to serine phosphorylation of IRS1, and alter the insulin 
signaling cascade77,78. Experimental work with PKC knockout mice demonstrates that it 
can protect mice from fat-induced insulin resistance 79. 
 
 
1.6 Aims of the study 
It has been previously shown that annexin A7 affects COX activity. These two key 
molecules participate in various metabolic processes. Furthermore, recent data indicates 
that insulin resistance has a strong association with COX activity and its metabolite 
PGE2. However the role of annexin A7 in glucose homeostasis remains unclear. 
Therefore, we pursued to investigate the role of annexin A7 in glucose regulation. Our 
hypothesis states that annexin A7 modifies COX activity and prostaglandin formation 
thereby impacting insulin sensitivity and glucose regulation.  
The aim of this study is to: 
l Explore the possible mechanism of annexin A7 on the regulation of serum glucose 
concentration  
l Describe the basic pathway leading to the effect of annexin A7 on glucose 
metabolism. 
l The role of ENaC and SGLT1 from colon and jejunum in vivo using A7 knockout 
mice 
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2. Materials and Methods. 
2.1 Materials 
2.1.1 Animals 
 
Experiments were performed in gene-targeted mice lacking annexin A7 (annexinA7-/-) 
and in corresponding wild type mice (annexinA7+/+). Generation, properties and 
genotyping of annexinA7-/- mice were described earlier 80. Male age-matched mice (9-15 
week-old) were used for the experiments. All animal experiments were conducted 
according to the German law for the care and use of animals and were approved by the 
responsible authority of the state of Baden-Württemberg (Regierungspräsidium 
Tübingen). Mice had free access to a standard chow diet (SSniff, Soest, Germany) and a 
tap water.  
 
2.1.2 Blood and Serum Collection  
 
Equipment and Chemicals 
 
Names Manufacturer and country of origin 
Diethylether 
Na-Heparin capillaries 
SST Tubes 
Centrifuge 5417 R 
Roth, Karlsruhe ,Germany 
HirschmannLaborgeräte, Eberstadt, Germany 
BD Microtainer, Franklin Lakes, USA 
Eppendorf, Hamburg, Germany 
 
2.1.3 Tolerance test 
 
Chemicals 
 
Names Manufacturer and country of origin 
D-Glucose 
Saline 
Phosphate buffered saline (PBS) 
Long-acting Insulin  
Sigma, Schnelldorf, Germany 
Fresenius Kabi, Bad Homburg, Germany 
GIBCO, Carsbad, Germany 
Lantus, Frankfurt, Germany 
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Equipment 
 
Names Manufacturer and country of origin 
Timer 
Syringe-driven Filter Unit 
Needles (0.55mm×25mm) 
Syringes (1ml) 
Accu-Chek Performa 
Glucose Meter 
Balance 
Scalpel 
Roth, Karlsruhe, Germany 
Millex Merk , Darmstadt, Germany 
BD, Drogheda, Ireland 
Braun, Bad Arolsen, Germany 
Roche, Mannheim, Germany 
Roche, Mannheim, Germany 
Sartorius, Göttingen, Germany 
Mediware, Wesel, Germany 
 
 
2.1.4 ELISA Measurement 
 
Equipment 
 
Names Manufacturer and country of origin 
Eppendorf pipettes 1ml, 200µL，
100µL,10µL 
Eppendorf tubes  
Centrifuge 5417R 
Stripette 5,10,25ml 
Vortex Genie 
Powerwaver XS2  
Utratip 
Shaker VIBRAX VXR 
MultiChanelPipet 
Eppendorf AG, Hamburg, Germany 
 
Eppendorf AG, Hamburg, Germany 
Eppendorf AG, Hamburg, Germany 
Coring Incorporated, Corning NY, USA 
Scientific Indusreies, Bohemia NY, USA 
BioTek Instruments, Inc. Winooski,USA 
Greiner bio-one, Frickenhausen, Germany 
IKA, Staufen, Germany 
Eppendorf, Hamburg, Germany 
 
ELISA Kits and Chemicals 
 
Names Manufacturer and country of origin 
Ultra Sensitive Mouse Insulin 
ELISA kit 
6-Keto-PGF1α Immunoassay Kit 
COX activity assay Kit 
PGE2 Immunoassay Kit 
Plasma Leptin ELISA Kit 
Ampuwa 
Crystal Chem INC, Downers Grove, IL, USA 
 
Biotrend, Köln, Germany 
Cayman, Ann Arbor,USA 
Demeditec, Kiel, Germay 
EMD Millipore, Missouri, USA 
Fresenius Kabi, Bad Homburg, Germany 
 
Software 
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Names Manufacturer and country of origin 
Sigma plot version 7.0 
GraphPad Instat version 3.05 
Systat Software Inc., Erkrath, Germany 
GraphPad Software Inc., San Diego, USA 
 
2.1.5 Ussing chamber measurement 
 
Equipment 
 
Names Manufacturer and country of origin 
Maclab/4e 
Pulse generator 5.1 
Mini Chamber 
Microscope 
Waterbath 
AD Instruments, Dunedin, New Zealand 
Custom made 
Custom made 
Carl Zeiss, Oberkochen, Germany 
Labortechnik, Seelbach, Germany 
 
Chemicals 
Names Manufacturer and country of origin 
NaCl 
KH2PO4 
K2HPO4×3H2O 
KCL 
MgCl2×6H2O 
Pyruvic Acid 
CaCl2×2H2O 
NaHCO3 
Calcium Gluconate 
Amiloride 
DMSO 
Carbogen 
VWR Chemicals, Darmstadt, Germany 
Roth, Karlsruhe ,Germany 
Merk, Darmstadt, Germany 
Roth, Karlsruhe ,Germany 
Merk, Darmstadt, Germany 
Sigma, Schnelldorf, Germany 
Sigma, Schnelldorf, Germany 
Sigma, Schnelldorf, Germany 
Sigma, Schnelldorf, Germany 
Sigma, Schnelldorf, Germany 
Sigma, Schnelldorf, Germany 
Westfalen AG, Muenster, Germany 
 
Software 
Names Manufacturer and country of origin 
Chart version.4.2 Axon Instruments, USA 
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2.1.6 Urine glucose Measurement 
 
Equipment and Chemicals 
 
Names Manufacturer and country of origin 
Eppendorf tubes 
Balance  
Metabolic cages   
Microtest 96wells 
Vortex 
Centrifuge 5417 R  
Eppendorf pipettes  
Ampuwa 
Glucose Kit 
 
 
Eppendorf AG, Hamburg, Germany 
Sartorius, Göttingen, Germany 
Techniplast, Hohenpeissenberg, Germany  
Falcon, Frankin Lakes, USA 
Labnet Abimed, Langenfeld, Germany 
Eppendorf, Hamburg, Germany 
Eppendorf AG, Hamburg, Germany 
Fresenius Kabi, Bad Homburg, Germany  
Roche Diagnostics, Mannheim, Germany 
 
2.2. Methods 
2.2.1 Serum Collection 
 
To obtain blood specimens, animals were lightly anesthetized with diethylether and 
approximately 130 µl of blood was withdrawn into heparinized capillaries by puncturing 
the retro-orbital plexus. After collection of the blood in SSD tubes, then centrifuged at 
6,000-8,000 g for 3-8 minutes in a refrigerated centrifuge. The resulting supernatant is 
designated serum. 
 
2.2.2 Animals Treatment 
 
For some experiments, mice were pretreated with aspirin in drinking water at a 
concentration of 600 mg/l for 1-2 weeks consecutively. 
 
2.2.3 Glucose Tolerance Test 
 
In order to detect disturbances in glucose metabolism, mice are fasted overnight and 
glucose (2g/kg b.w.) was injected intraperitoneally (i.p.). The blood glucose 
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concentration is determined before and at 15th, 30th, 45th, 60th, 90th, and 120th minute 
after the injection. The glucose concentration was measured in a drop of tail blood 
utilizing a glucometer. 
 
2.2.4 Insulin Tolerance Test 
 
For determine the insulin resistance in body, mice are fasted for 4 h, and long-acting 
insulin was injected i.p. (0.5 U/kg b.w.). The blood glucose concentration is determined 
before and at 15th, 30th, 45th, 60th, 90th, and 120th minute after the injection. The 
glucose concentration was measured in a drop of tail blood utilizing a glucometer. 
 
2.2.5 Determination of insulin, leptin and 6-Keto-PGF1α in plasma 
 
The serum insulin, leptin and 6-Keto-PGF1α concentrations were determined with an 
enzyme-linked immunosorbent assay (ELISA) method according to the manufacturer’s 
instructions. Results were derived using the standard curve method.  
 
2.2.6 Determination of PGE2 and COX activity in liver tissue 
 
The PGE2 concentration and COX activity in liver were determined with an ELISA 
method according to the manufacturer’s instructions. Results were derived using the 
standard curve method.  
 
2.2.7 Ussing Chamber Measurement 
 
For the analysis of electrogenic intestinal glucose transport, distal jejunal segments were 
taken from the intestine, and the muscle layers were carefully separated from the luminal 
layer under a microscope. The luminal tissue was then mounted into a custom-made 
mini-Ussing chamber with an opening of 0.00769 cm2. Under control conditions, the 
serosal and luminal perfusate for jejunal experiments contained (in mM): 115 NaCl, 2 
KCl, 1 MgCl2, 1.25 CaCl2, 0.4 KH2PO4, 1.6 K2HPO4, 5 Na pyruvic acid, 25 NaHCO3, 
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20 mannitol (pH 7.4, NaOH). The solutions were gassed with 5% CO2 prior to the 
Ussing chamber experiment, and the temperature was maintained at 37°C. Where 
indicated, glucose (20 mM) was added to the luminal perfusate at the expense of 
mannitol.  
 
ENaC activity was estimated from the amiloride-sensitive potential difference and 
current across the colonic epithelium. After removing the outer serosal and the muscular 
layer of late distal colon under a microscope, tissues were mounted onto a custom-made 
mini-Ussing chamber with an opening area of 0.00769 cm2. The serosal and luminal 
perfusate contained (in mM): 145 NaCl, 1 MgCl2, 2.6 Ca-gluconate, 0.4 KH2PO4, 1.6 
K2HPO4, 5 glucose. To assess ENaC mediated transport, 50 µM amiloride (in DMSO) 
was added to the luminal perfusate. All experiments were carried out at a temperature 
of 37°C. 
 
In all Ussing chamber experiments, the transepithelial potential difference (Vte) was 
determined continuously and the transepithelial resistance (Rte) was estimated from the 
voltage deflections (ΔVte) elicited by imposing test currents (It) of 1 µA. The resulting  
R te and I sc were calculated according to Ohm’s law. 81. 
 
2.2.8 Urine Collection and Urinary glucose Measurement 
 
For evaluation of the urinary glucose levels, mice were placed individually in metabolic 
cages for 24-hour urine and feces collection with free access to fluid and food. They 
were allowed a 3-day habituation period when food & water intake, urinary flow, urinary 
excretion of salt, fecal excretion and body weight were recorded every day to ascertain 
that the mice were adapted to the new environment. Subsequently 24h collection of urine 
was performed for three consecutive days in order to obtain the urinary parameters. To 
assure quantitative urine collection, metabolic cages were siliconized and urine was 
collected under water-saturated oil. Urinary glucose levels were determined by the 
Glucose kit according to the manufacturer’s instructions. 
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2.3 Statistical Analysis 
 
Data are provided as arithmetic means ± SEM, n represents the number of mice studied. 
Differences were tested for significance using Student´s unpaired two-tailed t-test, and 
only results with p < 0.05 were considered statistically significant. Microsoft Excel 2011 
and Graph pad Prism 6 were used for the calculation. 
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3. Results 
3.1 Higher serum 6-Keto-PGF1α levels in annexinA7-/- mice 
A previous study has reported higher levels of PGE2 in erythrocytes from mice lacking 
annexin A7 (annexinA7-/- mice)82. In the present study, due to the short half-life time 
(30s) of PGE2, it is difficult to determine accurately in vitro. Instead, the stable and end 
product of PGI2 metabolism 6-Keto-PGF1α was used to estimate serum COX-2 activity. 
We measured 6-Keto-PGF1α in serum from annexinA7-/- and annexinA7+/+ mice. Figure 
6 illustrates that the serum 6-Keto-PGF1α concentrations was significantly (*, p<0.05) 
higher in annexinA7-/- mice than in annexinA7+/+ mice pointing to higher COX-2 
activity in mice lacking annexin A7. 
 
 
 
 
Figure 6. Serum 6-Keto-PGF1α concentration in annexinA7+/+ and annexinA7-/- mice. 
Arithmetic means ± SEM (n = 6) of serum 6-Keto-PGF1α concentration from annexinA7+/+ 
(white bar) and annexinA7-/- mice (black bar).  
* indicates significant difference using Student's t-test(p<0.05). 
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3.2 Higher COX activity in annexinA7-/- mice liver 
The liver is the major organ involved in glucose metabolism. The COX activity was 
determined in liver tissue. As illustrated in Figure 7, the total COX activity levels of 
the liver in annexinA7-/- mice was higher than annexinA7+/+mice. The difference 
reached statistical significance (*, p<0.05). COX-1 activity in liver of annexinA7-/- mice 
was higher, but was not statically difference.   
 
A                             B 
     
                         
Figure 7. Liver total COX activity and COX-1 activity in annexin A7+/+ and annexin A7-/- 
mice.  
A. Arithmetic means ± SEM (n = 6) of the liver total COX activity of annexinA7+/+ (white bar) 
and annexinA7-/- mice (black bar).  
B. Arithmetic means ± SEM (n = 6) of the liver COX-1 activity of annexinA7+/+ (white bar) 
and annexinA7-/- mice (black bar).  
* indicates significant difference using Student's t-test (p<0.05). 
 
 
PGE2 concentration and COX-2 activity in liver tissue were also determined. In 
normal liver, COX-2 activity is either low or not detectable, but annexin A7 may 
modify the activity of COX-2. As shown in figure 8, PGE2 concentration and COX-2 
activity in liver tissue were higher in annexinA7-/- mice, however, not reaching 
statistical significance.  
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A                             B 
          
Figure 8. Liver COX-2 activity and PGE2 concentration in annexinA7+/+ and annexinA7-/- 
mice.  
A. Arithmetic means ± SEM (n = 6) of the liver COX-2 activity of annexinA7+/+ (white bar) 
and annexinA7-/- mice (black bar).  
B. Arithmetic means ± SEM (n = 4) of the PGE2 concentration in liver of annexinA7+/+ (white 
bar) and annexinA7-/- mice (black bar).  
 
3.3 Decreased glucose tolerance in annexinA7-/- mice 
 
Since COX activity and prostaglandins have been shown to negatively influence 
hepatic glucose tolerance, the fasted glucose levels were analyzed in annexinA7-/- mice 
and annexinA7+/+ mice. Following an overnight fasting period the blood glucose 
concentration was not significantly different in annexinA7-/- mice (73 ± 6 mg/dl, n =5) 
and annexinA7+/+ mice (66 ± 3 mg/dl, n =7) (Figure 9A). 
 
To test further for differences between annexinA7-/- mice and annexinA7+/+ mice in 
glucose metabolism, glucose tolerance was determined. After overnight fasting, an 
intraperitoneal glucose load (2 g/kg b.w.) was followed by a rapid increase in the blood 
glucose concentration (Figure 9B), which was more pronounced in annexinA7-/- mice 
than in annexinA7+/+ mice (Figure 9B). The difference of blood glucose concentration 
reached statistical significance before, and 15, 30, 45, and 60 min after the glucose load. 
These results suggest compromised glucose tolerance in annexinA7-/- mice. 
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Figure 9. Blood glucose concentration following intraperitoneal glucose injection in 
annexin A7+/+ and annexin A7-/- mice. 
A. Arithmetic means ± SEM (n = 5-7) of the overnight fast blood glucose concentration of 
annexinA7+/+ (white bar) and annexinA7-/- mice (black bar).  
B. Arithmetic means ± SEM (n = 17-18) of the blood glucose concentration following 
intraperitoneal injection of glucose (2 g/kg body weight) into annexinA7+/+ and annexinA7-/ 
mice. 
**, *** indicate significant difference using Student's t-test (p<0.01, p<0.001). 
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3.4 Lower insulin sensitivity of annexinA7-/- mice 
 
Decreased glucose tolerance in annexinA7-/- mice may be the consequence of reduced 
insulin sensitivity of peripheral glucose uptake or impaired insulin secretion. The next 
series of experiments therefore explored glucose-induced insulin secretion in annexin 
A7-/- and annexinA7+/+ mice. To this end, mice were fasted overnight, and glucose (2 
g/kg b.w.) was injected intraperitoneally. After 30 min, blood was drawn and serum 
insulin determined. Figure 10 illustrates that the serum insulin level was significantly 
higher in annexinA7-/- mice than in annexinA7+/+ mice following the glucose load. This 
result demonstrates intact insulin secretion in annexinA7-/- mice and suggests that 
rather reduced insulin sensitivity accounts for their decreased glucose tolerance. 
 
 
 
Figure 10. Insulin serum concentration before and after intraperitoneal glucose injection 
(GLU i.p.) in annexin A7+/+ and annexin A7-/- mice. 
Arithmetic means ± SEM (n = 12-14) of the serum insulin level 30 min after intraperitoneal 
injection of glucose (2 g/kg b.w.) into annexinA7+/+(white bar) and annexinA7-/-  (black bar) 
mice. 
* indicates significant difference using Student's t-test (p<0.05). 
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Hence, further experiments explored an impact of annexin A7 deficiency on the insulin 
sensitivity of peripheral glucose uptake. To this end, insulin was injected 
intraperitoneally (0.5 U/kg b.w.) after 4 hours of fasting and blood glucose concentration 
measured every 15 minutes. As illustrated in Figure 11, the insulin administration was 
followed by a decrease of the blood glucose concentration, which was significantly less 
pronounced in annexinA7-/- mice than in annexinA7+/+ mice pointing to decreased 
peripheral insulin sensitivity in annexinA7-/- mice. 
 
 
 
 
 
Figure 11. Blood glucose concentration following intraperitoneal insulin injection in 
annexinA7+/+ and annexinA7-/- mice. 
Arithmetic means ± SEM (n = 13) of the blood glucose concentration following intraperitoneal 
injection of insulin (0. 5 U/kg b.w.) into annexinA7+/+ and annexinA7-/- mice. The values are 
expressed as percentage of the blood glucose level at t = 0 min. 
*, **, *** indicate significant difference using Student's t-test (p<0.05, p<0.01, p<0.001). 
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3.5 Reduced glucose tolerance in annexinA7-/- mice depends on COX 
activity 
 
Further experiments were performed to elucidate whether the reduced glucose tolerance 
of annexinA7-/- mice was secondary to enhanced COX activity. Mice were treated with 
COX inhibitor aspirin and the glucose tolerance test was repeated. It is shown in Figure 
12 that in aspirin-treated animals the intraperitoneal glucose load (2 g/kg b.w.) was 
followed by an increase in the blood glucose concentration, which was less pronounced 
in annexinA7-/- mice than in annexinA7+/+ mice.  
 
 
 
Figure 12. Glucose tolerance in aspirin-treated annexinA7+/+ and annexinA7-/- mice. 
Arithmetic means ± SEM (n = 10-12) of the blood glucose concentration following 
intraperitoneal injection of glucose (2 g/kg body weight) into annexinA7+/+ and annexinA7-/-  
mice treated with aspirin (600 mg/l in drinking water) for 1-2 weeks. 
* indicates significant difference using Student's t-test (p<0.05). 
 
 
Since aspirin treatment markedly improved glucose tolerance in annexinA7-/- mice, 
insulin was again determined in aspirin-treated animals after a glucose load. In contrast 
to untreated mice, glucose-induced insulin secretion was lower in aspirin-treated 
annexinA7-/- mice and not significantly different from annexinA7+/+ mice (Figure 13). 
This result suggests an improvement of insulin resistance of aspirin-treated annexinA7-/- 
mice. 
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Figure 13. Glucose-induced insulin secretion in aspirin-treated annexinA7+/+ and annexin 
A7-/- mice. 
Arithmetic means ± SEM (n = 6-7) of the serum insulin level 30 min after intraperitoneal 
injection of glucose (2 g/kg b.w.) into annexinA7+/+ (white bar) and annexinA7-/-  (black bar) 
mice treated with aspirin (600 mg/l in drinking water) for 2 weeks. 
*** indicate significant difference using Student's t-test (p<0.001). 
 
3.6 Leptin levels in annexinA7+/+ and annexinA7-/- mice. 
 
Leptin secretion by white adipose tissue and plays a critical role in the regulation of 
food intake and maintenance the normal body weight. Leptin can regulate COX 
activity and stimulate PGE2 and PGF2α secretion by induce COX-2 activation83,84. To 
assess whether annexin A7 modifies the leptin level hereby affecting the COX activity, 
serum leptin concentration was measured. 
 
The results show the body weight of both genotypes were similar (22.73±0.67g and 
21.62±0.32g) in 12 week-old-mice (Figure 14A), the serum leptin concentration in 
annexinA7-/- mice was lower than annexinA7+/+ mice but without statistical significance 
(Figure 14B). 
 
 
 
 
 35 
A                           B 
     
 
Figure 14. Body weight and serum leptin concentration in annexinA7+/+ and annexinA7-/- 
mice. 
A. Arithmetic means ± SEM (n = 8, 12 weeks old) of the body weight of annexinA7+/+ (white 
bar) and annexinA7-/- mice (black bar).  
B. Arithmetic means ± SEM (n = 4) of the serum leptin concentration in annexinA7+/+ (white 
bar) and annexinA7-/- mice (black bar). 
 
 
3.7 Lower SGLT1 activity in jejunum of annexinA7-/- mice. 
 
Annexin A7 is expressed in the alimentary tract and related to gastric and colonic 
neoplasm22. The intestinal glucose absorption is mediated by SGLT1 and the jejunum is 
the major organ for the digestion and glucose absorption. To elucidate the influence of 
annexin A7 on the sodium-dependent glucose cotransporter-1 (SGLT1) activity and thus 
effects the blood glucose level, distal segments of jejunum from annexinA7-/- mice and 
annexin A7+/+ were mounted into mini-Ussing chambers and subjected to 
electrophysiological analysis. The transepithelial resistance (Rt) approached 
5.8±  0.4 Ω cm2 (n  =  5) in annexinA7+/+ mice and 6.6  ±  0.4 Ω cm2 (n  =  5) in annexinA7-/- 
mice (Figure 14A). Neither the transepithelial potential difference nor the transepithelial 
resistance was significantly different between annexinA7+/+ and annexinA7-/-. 
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Figure 15. Glucose-induced current in jejunum of annexinA7+/+ and annexinA7-/- mice. 
A. Arithmetic means means ± SEM (n = 5) resistance of intestine epithelium from annexinA7+/+   
(white bar) and annexinA7-/- (black bar) mice. 
B. Arithmetic means ± SEM (n = 5-11) of glucose-induced current in distal jejunum from 
annexinA7+/+ (white bar) and annexinA7-/-  (black bar) mice. 
C. Original tracings from typical experiments illustrating the effect of 20 mM glucose (addition 
indicated by black arrows) on the transepithelial potential difference in annexinA7+/+  (left panels) 
and annexinA7-/- (right panels) mice. 
** indicates significant difference using Student's t-test (p<0.01). 
 
The partial isosmotic replacement of mannitol by glucose created a lumen-negative shift 
of the transepithelial potential difference (ΔVg) without significantly altering the 
transepithelial resistance. ΔVg and Rt allowed the calculation of the glucose-induced 
current, which was significantly lower in annexinA7-/- than in annexinA7+/+ mice (**, 
P<0.01) (Figure 15). Accordingly, the SGLT1 activity was significantly lower in 
annexinA7-/- than in annexinA7-/- mice. However, we found higher glucose concentration 
in annexinA7+/+ mice. This result suggests that the activity of SGLT1 has no directly 
correlation with blood glucose level between annexinA7-/- and annexinA7+/+ mice.  
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3.8 Urinary glucose levels in annexinA7+/+ and annexinA7-/- mice.  
 
In the kidney, sodium-dependent glucose cotransporter-2 (SGLT2) plays a central role 
in glucose reabsorption. SGLT2 inhibitors have been applied in clinical treatment for 
diabetes mellitus85. In present study, urinary glucose was measured to estimate the 
activity of SGLT2. The result shown in figure 16, there was no significant difference 
between annexinA7+/+ and annexinA7-/- mice, indicating that annexinA7 can not 
modify the SGLT2 activity then thus affects the blood glucose. 
 
 
 
Figure 16. Urinary glucose concentration in annexinA7+/+ and annexinA7-/- mice. 
Arithmetic means ± SEM (n = 5) of the urinary glucose concentration of annexinA7+/+ (white 
bar) and annexin7-/- mice (black bar).  
 
 
3.9 Higher ENaC activity of colon in annexinA7-/- mice. 
 
The electrogenic amiloride-sensitive epithelial sodium channels (ENaC) are 
abundantly expressed in the distal colon. The activity of ENaC, which can be 
regulated by insulin and PGs, is related to the sodium balance, the blood volume and 
the blood pressure86-88. To evaluate whether annexin A7 influence on the ENaC activity, 
the ENaC activity in colon was determined by Ussing Chamber. 
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Figure 17. Amiloride-induced current in colon of annexinA7+/+ and annexinA7-/- mice. 
A. Arithmetic means means ± SEM (n = 4) resistance of colon epithelium from annexinA7+/+   
(white bar) and annexinA7-/- (black bar) mice. 
B. Arithmetic means ± SEM (n = 4) of amiloride-induced current in colon from annexinA7+/+ 
(white bar) and annexinA7-/-  (black bar) mice. 
C. Original tracings from typical experiments illustrating the effect of 50µM amiloride (addition 
indicated by black arrows) on the transepithelial potential difference in annexinA7+/+  (left panels) 
and annexinA7-/- (right panels) mice. 
* indicates significant difference using Student's t-test (p<0.05). 
 
As illustrated in Figure 17, the transepithelial resistance (Figure 17A) between 
annexinA7+/+ and annexinA7-/- mice have no significantly difference, but the amiloride 
sensitive current was significantly increased in annexinA7-/- mice (*, P<0.05)(Figure 
17B). This result suggests that annexin A7 downregluate ENaC activity and may 
affect the blood pressure. 
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4. Discussion 
 
Annexin A7 is a widely conserved gene including fungi, protists, plants and vertebrates 
and has been shown to be involved in many different cellular processes, some of 
which implicate COX upregulation that occurs in a variety of pathophysiological 
conditions including diabetes mellitus. To assess whether annexin A7 was a negative 
effect on the glucose metabolism, gene-targeted mice lacking annexin A7 mice 
(annexinA7-/-) were used to compare wild-type mice (annexinA7+/+). Our studies 
reveal a novel function of annexin A7 in the regulation of cellular glucose uptake. 
Increase in serum glucose concentration following an intraperitoneal glucose load was 
significantly higher annexinA7-/- mice than in corresponding wild type mice. The 
observations point to impaired glucose uptake in annexin A7 deficiency. Glucose 
uptake is decreased in annexinA7-/- mice despite a sharper increase of insulin plasma 
levels following a glucose load in annexinA7-/- mice as compared to annexinA7+/+ 
mice. Accordingly, the hyperglycemia reflects insulin resistance of cellular glucose 
uptake. The decline of plasma glucose concentration following injection of insulin 
was significantly blunted in annexin A7 deficient mice.  
 
 
4.1 The effect of annexin A7 deficiency on glucose tolerance 
 
The present observations found an increase of serum glucose concentration in 
annexinA7-/- mice was significantly higher than in annexinA7+/+ mice after an 
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intraperitoneal glucose load. The maintenance of normal glucose homeostasis depends 
on a finely balanced dynamic interaction between insulin secretion and cellular 
sensitivity to insulin. Insulin production disorder can lead to type 1 diabetes mellitus. 
Reduced cellular sensitivity to insulin can lead to abnormal glucose metabolism and 
form type 2 diabetes mellitus. Type 2 diabetes mellitus pathogenesis is multifactorial 
process and the precise mechanisms remain unclear.  
 
We postulate that impaired insulin secretion or impaired cellular glucose uptake in 
part due to annexin A7 deficiency. In order to verify this hypothesis, insulin 
concentration in mice serum was determined. Prior to an intraperitoneal glucose load, 
the basal concentration of serum insulin was lower in annexinA7-/- mice and 
annexinA7+/+ mice, without statistical significance. However, after glucose loading, 
the concentration of serum insulin increased more in annexinA7-/- mice than 
annexinA7+/+ mice within 30 minutes. This result demonstrates that impaired insulin 
production in annexinA7-/- does not account for their decreased glucose tolerance.  
 
Insulin is the primary factor for cellular glucose uptake in normal metabolism. Insulin 
decreases the blood glucose levels mainly by promoting glucose uptake into cells, 
stimulating glycogen synthesis in liver and skeletal muscle. Insulin tolerance test was 
applied to assess the impact of annexin A7 deficiency on the insulin sensitivity of 
peripheral glucose uptake. The result revealed an impaired insulin effect on the blood 
glucose level in annexinA7-/- mice. This indicates that annexinA7-/- mice have 
peripheral insulin resistance. Interestingly, the heterozygote mouse model of annexin 
A7 deficiency (annexinA7+/-mice) exhibited higher receptor-dependent 
glucose-induced insulin secretion 89. 
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Defective insulin signaling and action may cause the impairment of insulin action and 
lead to insulin resistance. Annexin A7 is related to the Ca2+ and phospholipid-binding 
protein in tissue and has a strong association with cellular protein function and 
defective intracellular calcium signaling80. Hence, annexin A7 deficiency can affect 
proteins, receptors or transporters that are related to the insulin function and thereby 
induce the insulin resistance. Further studies are required to confirm the effect of 
annexin A7 on those factors. 
 
4.2 The mechanism of annexin A7 impacting on insulin sensitivity 
 
The insulin resistance was at least partially due to enhanced COX activity in annexin 
A7-deficient mice. Enhanced formation of PGE2, a by-product of COX-2 metabolism, 
in annexinA7-/- mice has already been observed in erythrocytes 90. COX-2 is a critical 
mediator in inflammation and immune cell reaction. Inflammation, which is an 
important factor in the pathogenesis of type 2 diabetes mellitus, can induce insulin 
resistance91. Lately, research has suggested that chronic subclinical inflammation state 
may be an underlying mechanism for the insulin resistance92. Prostaglandins, which 
act as signaling intermediates, can also mediate the insulin resistance process. 
Overproduction of prostaglandin D2 (PGD2) can increase insulin resistance through 
enhance lipophilic molecules in fat 93. Elevated spinal COX-2 protein expression and 
PGE2 release were observed in diabetic rats94. As outlined in the introduction, glucose 
is taken up into muscle through insulin-sensitive GLUT4. It was suggested that 
COX-2 can regulate and decrease GLUT4 expression in vitro95. 
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Our studies showed deranged glucose metabolism which was paralleled by elevated 
serum levels of 6-Keto-PGF1α, which is a stable end product of prostaglandin 
metabolism indicating COX-2 activity 96,97. Moreover, a COX enzyme assay revealed 
higher hepatic COX activity in annexinA7-/- mice than annexinA7+/+ mice. Recently, 
PGE2 has been shown to cause insulin resistance in hepatocytes through affecting the 
function of insulin receptor substrate and preventing an insulin-dependent activation of 
AKT and glycogen synthesis98. Prostaglandins may therefore contribute to deranged 
glucose metabolism in type 2 diabetes mellitus 98. Thus, we further provide evidence 
that hepatic COX activity is, at least in part, regulated by annexin A7. 
In order to elucidate whether the impaired glucose tolerance of annexinA7-/- mice was 
related to the enhance COX activity, mice were treated with COX inhibitor aspirin. 
Aspirin can decrease prostaglandins production and reduce inflammation through 
binding and inhibiting COX enzyme. It has been suggested that aspirin can enhance 
the insulin sensitivity by keeping IRS away from other kinases that may reduce IRS 
activity99. The beneficial effect of COX inhibition on glucose intolerance has been 
reported earlier in a study showing that aspirin treatment ameliorates peripheral insulin 
resistance 100.  
 
In line with enhanced COX activity in annexinA7-/- mice, the difference in glucose 
tolerance between annexinA7-/- mice and annexinA7+/+ mice was reversed by treating 
the mice with aspirin. Moreover, aspirin treatment of annexinA7-/- mice reduced 
glucose-induced insulin secretion.  
 43 
Notably, the effect of annnexin A7 deficiency on parasitemia and clinical course of 
malaria and the blunted stimulation of gastric acid secretion by dexamethasone were 
similarly reversed by inhibition of cyclooxygenase with aspirin 90,23. Accordingly, the 
phenotype of annexinA7-/- mice is at least partially due to inhibition of cyclooxygenase. 
This observation does, however, not rule out that further other annexin A7 sensitive 
mechanisms contribute to the regulation of glucose metabolism. 
 
4.3 The effect of annexin A7 on SGLT1 and ENaC activity 
 
SGLT1 is the primary intestinal glucose transporter. SGLT1 expression is under an 
indirect control by insulin and increased in type 2 diabetes mellitus101,102. The mice 
lacking SGLT1 or inhibition of SGLT1 activity can improve glucose tolerance103. 
Interestingly, the activity of SGLT1 was significantly lower in annexinA7-/- mice. 
Current research suggests that PGE2 inhibits SGLT1 by reducing the cotransporter 
expression104. We report that COX activity and PGI2 end product 6-Keto-PGF1α were 
significantly higher in annexinA7-/- than annexinA7+/+ mice. This data imply that 
SGLT1 activity in jejunum is regulated by annexin A7. 
 
Hypertension is part of insulin resistance syndrome and ENaC is a key protein in 
regulation of blood volume and blood pressure105. It has been observed that PGE2 
induces ENaC upregulation in the mouse cortical collecting duct cells and in Xenopus 
lung epithelium106,107. Recent studies reveal the activation of ENaC can trigger the 
PGE2 formation and release in embryo implantation108, demonstrating the action of 
PGE2 and ENaC may be mutual. Moreover, insulin can also enhance the ENaC 
activity by increasing its channel density109. We report that higher ENaC activity in 
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annexinA7-/- mice. Thereby, Annexin A7 may regulate the ENaC activity and affect the 
blood pressure. 
 
Figure 18. The mechanism of annexin A7 impacting on insulin sensitivity. 
 
In summary (figure 18), annexin A7 inhibits COX activity then reducing PGE2 
synthesis. Insulin sensitivity is decreased by PGE2. In annexin A7-deficient mice, we 
also found insulin sensitivity was attenuated through the treatment of aspirin. 
Therefore, annexin A7 enhances the insulin sensitivity through its COX inhibition. 
PGE2 can reduce SGLT1 activity and decrease the glucose absorption in the jejunum. 
Due to the insulin resistance exist in annexin A7-deficient mice, however, blood 
glucose levels cannot reflect the difference of SGLT1 activity. Further studies will be 
required to evaluate the effect of annexin A7 on SGLT1 expression, cellular 
localization and activity. Annexin A7 can also decrease ENaC activity through 
reducing PGE2 synthesis. Higher ENaC activity is associated with hypertension and 
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diabetes mellitus. Blood pressure in annexin A7-deficient mice and ENaC expression 
should be future investigated.  
 
The clinical relevance of this finding is reinforced by the observation that the COX-2 
higher expression in vascular endothelial cells, islets of langerhans and peripheral 
nerve of type 2 diabetes mellitus patients, when compared to non-diabetic 
individuals110-112. Inflammation, especially the chronic subclinical inflammation state, 
is an underlying mechanism for the insulin resistance in type 2 diabetic mellitus. Our 
findings have revealed that annexin A7 deficiency or mutation may aggravate insulin 
resistance in diabetes. Lack of samples from diabetic patients is a limitation of our 
study. Nevertheless, we found a significant correlation between annexin A7 and COX 
activity as well as insulin resistance. Annexin A7 may be a novel therapeutic target 
for clinical application for type 2 diabetes mellitus in the future. 
 
Conclusion 
Annexin A7 deficiency decreases the insulin sensitivity of cellular glucose uptake, an 
effect virtually abrogated by inhibition of cyclooxygenase with aspirin. Annexin A7 
deficiency increases the ENaC activity in the colon possibly leading to high blood 
pressure. Annexin A7 deficiency decreases the Sglt1 activity in the jejunum lowering 
glucose absorption. 
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5. Zusammenfassung 
Hintergrund: Die Insulinsensitivität wird durch PGE2, ein Hauptprodukt der 
Cyclooxygenase 2 (COX-2), gestört, welches nach Glukosegabe die zelluläre 
Glukoseaufnahme beeinflusst. Wie schon in Erythrozyten gezeigt werden konnte, wird 
die PGE2-Bildung durch Annexin A7 gehemmt. Die vorliegende Arbeit ermittelte die 
Rolle von Annexin A7 im Glukosemetabolismus. 
 
Methoden: Mäuse mit gezielter Annexin A7 Genausschaltung wurden mit 
Wildtypmäusen verglichen. 6-Keto-prostaglandin-F1α wurde mit enzymgekoppeltem 
Immunadsorptionstest (ELISA) gemessen um die COX-2-Aktivität im Serum zu 
bestimmen. Die Hepatische COX-Aktivität wurde durch ELISA bestimmt. Die 
Serumkonzentrationen von Glukose und Insulin wurden nach intraperitonealer Gabe von 
Glukose und das Serum-Glukoselevel nach intraperitonealer Injektion von Insulin  
bestimmt. Die Experimente wurden jeweils mit und ohne Vorbehandlung der Mäuse mit 
dem COX-Inhibitor Aspirin durchgeführt. 
 
Resultate: Das 6-Keto-prostaglandin-F1α-Level im Serum und die hepatische 
COX-Aktivität waren signifikant höher in Annexin A7 Knockout-Mäusen als in 
Wildtyp-Mäusen. Der intraperitoneale Glukosetoleranztest brachte eine erniedrigte 
Glukosetoleranz in Annexin A7 Knockout-Mäusen verglichen mit Wildtyp-Mäusen zum 
Vorschein. Das Serum-Glukoselevel wurde durch eine intraperitoneale Insulininjektion 
in beiden Genotypen erniedrigt, ein Effekt, welcher signifikant weniger ausgeprägt in 
Annexin A7 Knockout als in Wildtyp-Mäusen war. Die intraperitoneale Gabe von 
Glukose führte zu höheren Serum-Insulinkonzentrationen in Annexin A7 
Knockout-Mäusen als in Wildtyp-Mäusen. Die Aspirinvorbehandlung verringerte die 
Erhöhung der Insulinkonzentration nach Glukoseinjektion in beiden Genotypen und hob 
den Unterschied der Insulinkonzentration im Serum nahezu auf. Zudem verbesserte die 
Aspirinvorbehandlung die Glukosetoleranz in Annexin A7 Knockout-Mäusen. 
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Schlussfolgerung: Annexin A7 beeinflusst die Insulinsensitivität bei Glukoseaufnahme 
und damit die Glukosetoleranz. Diese Effekte sind von der COX-Aktivität abhängig. 
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